Therapeutic Solutions International (TSOI)

Executive Summary

Therapeutic Solutions International (TSOI) is a U.S.-based biotechnology holding company focused on developing and commercializing novel cell and gene therapies. Founded in 2007 and headquartered in Oceanside, California, the company operates through a family of subsidiaries via licensing agreements, conducting all clinical research under these entities. Despite a long history, TSOI remains a micro-cap with a valuation of approximately $512,000 and no disclosed revenue or clinical-stage products, indicating a highly speculative investment. The company's strategy centers on acquiring and advancing early-stage therapeutic candidates, but lack of transparent pipeline details and minimal market presence suggest significant execution risk. TSOI aims to capitalize on the growing cell and gene therapy market, though its ability to secure partnerships, funding, or regulatory milestones remains unproven. Investors should approach with caution given the opaque business model and absence of near-term value drivers.

Upcoming Catalysts (preview)

• Q3 2026FDA IND Clearance for Lead Cell Therapy Candidate30% success
• Q4 2026Exclusive Licensing Agreement with Academic Institution25% success
• Q2 2026Announcement of Preclinical Data for Gene Therapy Program40% success